Menopause Claims Back Under the Spotlight Following ASA Review

Why It Matters

The rulings illustrate how strict advertising standards can limit how supplement makers communicate benefits, potentially curbing market expansion and consumer awareness of menopause support options.

Key Takeaways

• ASA cited Lunera, Minerva, Nova for illegal health claims
• Ads claimed treatment of menopause symptoms, violating CAP code
• Companies lacked evidence for metabolism or estrogen claims
• Lunera withdrew ads; others did not respond
• Industry leaders urge relaxed rules on women’s health marketing

Pulse Analysis

The ASA’s recent enforcement action reflects a broader push to tighten claims around food supplements, especially those targeting sensitive health periods like menopause. By leveraging AI‑assisted monitoring, the regulator identified ads that crossed the line from permissible structure‑function statements into prohibited disease‑treatment territory. The flagged messages not only promised symptom relief but also implied hormonal restoration, a claim reserved for licensed medicines. This distinction is critical under the CAP code and the GB Nutrition and Health Claims Register, which demand robust scientific evidence before any metabolic or estrogen‑related benefit can be advertised.

For supplement manufacturers, the fallout translates into heightened compliance costs and a need for more rigorous pre‑launch review processes. Brands must now invest in regulatory expertise, third‑party testing, and clear documentation to substantiate any health‑related claim. The uncertainty also affects marketing strategies; companies may shift toward educational content that avoids direct efficacy language, potentially limiting the ability to differentiate products in a crowded market. Consumers, meanwhile, receive fewer explicit assurances about product performance, which could dampen purchasing confidence and slow growth in the menopause‑support segment, a market projected to reach several billion dollars globally.

The controversy has sparked a debate among industry leaders who argue that current rules over‑medicalize women’s health and stifle honest communication. Calls for reform focus on allowing “structure‑function” claims when backed by credible ingredient data, similar to practices in the United States. If regulators adopt a more nuanced approach, it could unlock clearer messaging, foster innovation, and improve consumer access to evidence‑based menopause support. Until then, brands must navigate a delicate balance between compliance and effective outreach, making regulatory foresight a strategic priority.